KLP Kapitalforvaltning AS Invests $19.89 Million in Hologic, Inc. (NASDAQ:HOLX)

KLP Kapitalforvaltning AS bought a new position in Hologic, Inc. (NASDAQ:HOLX) during the fourth quarter, Holdings Channel reports. The firm bought 275,922 shares of the medical equipment provider’s stock, valued at approximately $19,891,000.

Other hedge funds have also recently modified their holdings of the company. First Horizon Advisors Inc. boosted its position in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares in the last quarter. Brooklyn Investment Group boosted its position in Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after purchasing an additional 145 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC boosted its position in Hologic by 2.1% during the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock worth $602,000 after purchasing an additional 169 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its position in Hologic by 29.3% during the third quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock worth $66,000 after purchasing an additional 183 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on HOLX shares. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $80.00 to $75.00 in a report on Thursday, February 6th. BNP Paribas raised Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Needham & Company LLC cut Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price for the company. in a report on Monday, February 3rd. Evercore ISI reduced their target price on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a report on Thursday, February 6th. Finally, Jefferies Financial Group started coverage on Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price for the company. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Hologic currently has a consensus rating of “Hold” and a consensus price target of $84.62.

Hologic Trading Up 0.8 %

Shares of Hologic stock opened at $61.47 on Monday. The firm has a market capitalization of $13.79 billion, a price-to-earnings ratio of 19.39, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a fifty-two week low of $60.34 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The stock has a 50 day moving average of $66.06 and a 200 day moving average of $73.94.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.